
ENERGENESIS — Investor Relations & Filings
Energenesis Biomedical Co., Ltd. specializes in the research and development of innovative pharmaceuticals through its proprietary ENERGI drug development platform. The company focuses on the activation of AMP-activated protein kinase (AMPK), a critical enzyme for cellular energy regulation, to develop therapeutic solutions for various diseases. Its core pipeline centers on small molecule purine compounds designed to modulate cellular energy metabolism. Operating with an intellectual property-driven strategy, the company manages the development cycle from early-stage drug discovery through clinical trial validation. Energenesis Biomedical aims to increase the value of its proprietary technologies for strategic out-licensing and collaboration with global pharmaceutical partners. In addition to drug development, the company offers specialized testing and analysis services and distributes research reagents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 114年度股利金額(董事會決議) | 2026-05-22 | Chinese | |
| 115年第1季財務報告書 — 202601_6657_AI1.pdf | 2026-05-13 | Chinese | |
| 115年第1季海外子公司投資 | 2026-05-11 | Chinese | |
| 115年第1季權益變動表 | 2026-05-11 | Chinese | |
| 115年第1季現金流量表 | 2026-05-11 | Chinese | |
| 115年第1季綜合損益表 | 2026-05-11 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46778242 | 114年度股利金額(董事會決議) | 2026-05-22 | Chinese | ||
| 46338951 | 115年第1季財務報告書 — 202601_6657_AI1.pdf | 2026-05-13 | Chinese | ||
| 45740777 | 115年第1季海外子公司投資 | 2026-05-11 | Chinese | ||
| 45746274 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45741609 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741439 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45741235 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
| 39978408 | 114年第4季財務報告書 — 202502_6657_AIA.pdf | 2026-04-30 | English | ||
| 39871803 | 114年第4季財務報告書 — 202501_6657_AIA.pdf | 2026-04-30 | English | ||
| 39871783 | 114年第4季財務報告書 — 202501_6657_AI1.pdf | 2026-04-30 | Chinese | ||
| 39886223 | 114年第4季財務報告書 — 202504_6657_AIC.pdf | 2026-04-30 | English | ||
| 39886197 | 114年第4季財務報告書 — 202504_6657_AIA.pdf | 2026-04-30 | English | ||
| 39886176 | 114年第4季財務報告書 — 202504_6657_AI3.pdf | 2026-04-30 | Chinese | ||
| 39886119 | 114年第4季財務報告書 — 202504_6657_AI1.pdf | 2026-04-30 | Chinese | ||
| 39886095 | 114年第4季財務報告書 — 202503_6657_AIA.pdf | 2026-04-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Jeevan Scientific Technology Limited
A CRO providing Phase I-IV trials, BA/BE research, and phar…
|
538837 | IN | Professional, scientific and te… |
|
J. Molner AS
A CDRO developing generic sterile injectable and dermatolog…
|
JML | EE | Professional, scientific and te… |
|
JOINN Laboratories (China) Co., Ltd.
Comprehensive CRO providing end-to-end preclinical drug dis…
|
6127 | HK | Professional, scientific and te… |
|
JOINN LABORATORIES (CHINA) CO., LTD.
A CRO specializing in non-clinical safety assessment and ph…
|
603127 | CN | Professional, scientific and te… |
|
Kadimastem Ltd.
Clinical-stage cell therapy company developing treatments f…
|
KDST | IL | Professional, scientific and te… |
|
KAINOS MEDICINE, INC.
Develops small molecule therapeutics for neurodegenerative,…
|
284620 | KR | Professional, scientific and te… |
|
Kairos Pharma, LTD.
Develops oncology therapies targeting drug resistance and i…
|
KAPA | US | Professional, scientific and te… |
|
Kancera
Pharmaceutical company seeking a reverse takeover to levera…
|
KAN | SE | Professional, scientific and te… |
|
KAZIA THERAPEUTICS LTD
Oncology-focused biotech developing targeted therapies for …
|
KZIA | US | Professional, scientific and te… |
|
Keros Therapeutics, Inc.
Develops protein therapeutics for disorders linked to TGF-β…
|
KROS | US | Professional, scientific and te… |
ENERGENESIS via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52601/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52601 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52601 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52601 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52601}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ENERGENESIS (id: 52601)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.